Estimation of Fasting Blood Glucose and Lipid Profile among Patients with Psychotics Disorders under Medications

  • AbdElkarim A. Abdrabo Department of clinical chemistry, Faculty of Medical Laboratory Sciences, Sudan International University, Sudan.
  • Shaimaa M. Sheek Department of clinical chemistry, Faculty of Medical Laboratory Sciences, Sudan International University, Sudan.

Abstract

Background: Individuals who are treated with antipsychotic medications especially atypical group are facing several metabolic and biochemical changes that might put them at higher risk of developing several diseases. The aim of this study was to evaluate the fasting blood glucose level and lipid profile among those with common psychotic disorders under effect of atypical antipsychotic drugs compared with healthy population.


Materials and Methods: A laboratory- based case control study was conducted and carried out in Khartoum State (AlTigani AlMahy Hospital for Psychotic and Mental Diseases) from May to November 2017. The samples were drawn from fifty patients of common psychotic disorders as case group and another fifty from healthy individuals as control group to estimate the level of fasting blood glucose and lipid profile using Mindary Biosystems PS200.


Results: out of 50 cases, 52% were males and 48% females. It was found that there was a significant increase in mean of all tested parameters, fasting blood glucose (FBG) (109.19±26.27), Total Cholesterol (167.23±41.79), Triglyceride (161.80±59.29) and Low Density Lipoprotein (LDL) (66.42±16.72) but decrease in High Density Lipoprotein (HDL) (53.96±17.86), all with (p.value 0.00) compared to control. There was no correlation between parameters and age, but positive correlation was observed between LDL and duration (R-0.047). 


Conclusion: Individuals under atypical antipsychotic medications had higher levels of fasting blood glucose and lipid profile than normal individuals.

References

1. Burger, Alfred, Drugs affecting the central nerves system, 2010, chapter 9, P 153.
2. Marco M Picchioni, Robin M Murray, Schizophrenia, Clinical Review, 2007; 335:91-5.
3. Hilty, Leamon, Lim et al, A Review ofBipolar Disorder in Adults,Psychiatry 2006.
4. David J Kupfer and Mary L Phillips, Major depressive disorder: new clinical, neurobiological, and treatment perspectives, NIH Public Access, March 17; 379(9820): 1045–1055.
5. Charles, Clare, What Evidence There To Show Which Antipsychotics Are More Diabetogenic Then Others? , Psychiatria Danubina, 2015; Vol. 27, Suppl 1, pp423–428.
6. Gianna Sepede1, Marco Lorusso, Maria Chiara Spano, et al, Substance Use in Schizophrenia: Efficacy of Atypical Antipsychotics, J Schizophr Res 2014, 1, 2471-0148.
7. Jean Linden Mayer, Pal Czobor, Jan Volanva, et al, Changes in Glucose and Cholesterol Levels in Patients with Schizophrenia Treated with Typical or Atypical Antipsychotics, American Journal psychiatry, 2003, 160:290-296.
8. Joseph A. Lieberman, Metabolic Changes Associated with Antipsychotic Use, Prim Care Companion J Clin Psychiatry 2004; 6[suppl 2]:8–13.
9. Minji Sohn, Jeffery Talbert, Karen Blumenschein, and Daniela Claudia Moga, Atypical antipsychotic initiation and the risk of type II diabetes in children and adolescents , Pharmacoepidemiol Drug Saf. 2015 June; 24(6): 583–591.
10. P. Gardner-Sood, J. Lally, S. Smith, et al, Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the impact randomized controlled trial, Psychological Medicine (2015), 45, 2619–2629.
11. Helen Watkinson, Peter Gallagher, et al, Metabolic disease and cardiovascular risk in people treated with antipsychotics, British Journal of Psychiatry (2007), 191, 23 - 29.
12. Joseph McEvoy, Rebecca A. Baillie, Hongjie Zhu, et al , Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics, Lipidomics of First Time and Chronic Schizophrenia, July 2013 ,8,7,e68717.
13. Johnson DE, Yamazaki H, Ward KM, et al, Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perfused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005 May; 54(5):1552-8.
14. Hamidreza Roohafza, AzamKhani, Hamid Afshar, et al, Lipid profile in antipsychotic drug users: A comparative study, Arya Atheroscholer 2013; May, Vol 9, 3.
15. Amita Gupta, S.B Petkar, A.A Jadhav, Vaibhav Dubey, Study of Lipid Derangement in Pyschiatric Disorder, Indian Medical Gazette, July 2013, 462, 010.
16. David C. Henderson, Enrico Cagliero, Paul M Copeland, et al , Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents , Arch Gen Psychiatry.2005; 62:19-28.
17. Jyoti Kaushal, , Garima Bhutani, Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone, Singapore M Original Article ed J 2012; 53(7) : 488.
Published
2019-12-31
How to Cite
ABDRABO, AbdElkarim A.; SHEEK, Shaimaa M.. Estimation of Fasting Blood Glucose and Lipid Profile among Patients with Psychotics Disorders under Medications. Gezira Journal of Health Sciences, [S.l.], v. 15, n. 2, dec. 2019. ISSN 1810-5386. Available at: <http://journals.uofg.edu.sd/index.php/gjhs/article/view/1409>. Date accessed: 01 oct. 2020.
Section
Articles